Extended Low-Dose Apixaban Reduces Risk of Recurrent VTE: HI-PRO Trial Results
Sina Rashedi, Postdoctoral Research Fellow at Brigham and Women’s Hospital, Harvard Medical School, shared a post on X:
”Honored to be a part of the HI-PRO trial, presented today by my mentor Gregory Piazza at ESC Congress 2025
Published in NEJM.
In provoked VTE and enduring risk,
Extended low-dose apixaban vs placebo:
Decreased risk of recurrent VTE with low risk of major.”
Read the full article here.
Title: Apixaban for Extended Treatment of Provoked Venous Thromboembolism
Authors: Gregory Piazza, Behnood Bikdeli, Arvind K. Pandey, Darsiya Krishnathasan, Candrika D. Khairani, Antoine Bejjani, Ruth H. Morrison, Heather Hogan, Sina Rashedi, Mariana Pfeferman, Junyang Lou, John Fanikos, Nicole Porio, Lisa Rosenbaum, Piotr Sobieszczyk, Zhou Lan, Marie Gerhard-Herman, Umberto Campia, Samuel Z. Goldhaber
Stay updated on the latest scientific advancements with Hemostasis Today.
-
Sep 2, 2026, 09:52Rick Matthews: Expanding Mechanical Thrombectomy to Coronary Arteries
-
Sep 2, 2026, 09:49Yara Dixon: Barriers and Facilitators to Blood Donation Across Diverse Populations
-
Sep 2, 2026, 09:29Ana Sachetto: Liver Injury and Tissue Factor-Driven Coagulation
-
Sep 2, 2026, 09:28Kavya Keerthana: A Potentially Important Advance in Polycythemia Vera
-
Sep 2, 2026, 09:26Mohammad Zuryan: Pre-Marital Genetic Screening for Thalassemia Prevention
-
Sep 2, 2026, 09:23Mohammed Salman: 9 Key Changes in the Fifth Universal Definition of Myocardial Infarction
-
Sep 2, 2026, 07:02Christoph B. Olivier: Rapid Platelet Inhibition in Acute Coronary Syndromes
-
Sep 2, 2026, 06:38Gene Therapy for Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
-
Sep 2, 2026, 06:32Sanjay Batra: Exploring What Lies Beyond Platelet Counts